Ancestry and pharmacogenetics of antileukemic drug toxicity

Blood

Volumn 109, Issue 10, 2007, Pages 4151-4157

  Kishi, Shinji ^a   Cheng, Cheng ^a   French, Deborah ^a   Pei, Deqing ^a   Das, Soma ^b   Cook, Edwin H ^b   Hijiya, Nobuko ^a,c   Rizzari, Carmelo ^d   Rosner, Gary L ^e   Frudakis, Tony ^f   Pui, Ching Hon ^a,c   Evans, William E ^a,c   Relling, Mary V ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b The University of Chicago   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f DNAPrint Genomics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450 3A5; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FOLIC ACID ANTAGONIST; GLUCURONOSYLTRANSFERASE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; STEROID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHILD; CONSTIPATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHENOTYPE; PLESIOMORPHY; PRIORITY JOURNAL;

EID: 34248379711     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-054528     Document Type: Article

References (46)

1. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-1548.
3. Schrappe M, Camitta B, Pui CH, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:2193-2194.
4. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-1218.
5. Rivera GK, Evans WE, Kalwinsky DK, et al. Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia. J Clin Oncol. 1985;3:201-206.
6. Winick NJ, Bowman WP, Kamen BA, et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst. 1992;84:252-256.
7. Gunnars B, Nygren P, Glimelius B. Assessment of quality of life during chemotherapy. Acta Oncol. 2001;40:175-184.
8. Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640-649.
9. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-1743.
10. Meadows AT, Robison LL, Neglia JP, Sather H, Hammond D. Potential long-term toxic effects in children treated for acute lymphoblastic leukemia. N Engl J Med. 1989;321:1830-1831.
11. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
12. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537.
13. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5- fluorouracil-induced toxicity. J Clin Invest. 1988;81:47-51.
14. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101:847-854.
15. Kishi S, Griener JC, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003;21:3084-3091.
16. Aplenc R, Glatfelter W, Han P, et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2003;122:240-244.
17. Naoe T, Tagawa Y, Kiyoi H, et al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia 2002;16:203-208.
18. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA. 2005;293:1485-1489.
19. Relling MV, Yang W, Das S, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol. 2004;22:3930-3936.
20. Arndt C, Hawkins D, Anderson JR, et al. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol. 2004;22:1894-1901.
21. Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;123:100-102.
22. Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005;105:4752-4758.
23. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-2696.
24. Gururangan S, Horner M, Rodman JH, Marina NM. Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis. Med Pediatr Oncol. 1994;22:414-416.
25. Ravindranath Y. Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer. 2005;44:1-7.
26. PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base. Available at: http://www.pharmgkb.org/. Accessed March 15, 2007.
27. Rubnitz JE, Relling MV, Harrison PL, et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia. 1998;12:1176-1181.
28. Frudakis T, Thomas M, Gaskin Z, et al. Sequences associated with human iris pigmentation. Genetics. 2003;165:2071-2083.
29. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003;348:1170-1175.
30. Holm S. A simple sequentially rejective multiple test procedure. Scan J Stat. 1979;6:65-70.
31. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
32. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1:99-108.
33. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther. 1985;28:77-102.
34. Whetstine JR, Gifford AJ, Witt T, et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res. 2001;7:3416-3422.
35. Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000;70:310-315.
36. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood. 2002;100:3832-3834.
37. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171-1175.
38. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet. 1996;347:578-581.
39. Rajaonarison JF, Lacarelle B, Catalin J, Durand A, Cano JP. Effect of anticancer drugs on the glucuronidation of 3′-azido-3′- deoxythymidine in human liver microsomes. Drug Metab Dispos. 1993;21:823-829.
40. Sainz J, Van Tornout JM, Loro ML, et al. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N Engl J Med. 1997;337:77-82.
41. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367:284-287.
42. Kishi S, Yang W, Boureau B, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood. 2004;103:67-72.
43. Thummel KE, Brimer C, Yasuda K, et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25- dihydroxy vitamin D3. Mol Pharmacol. 2001;60:1399-1406.
44. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008.
45. Choudhry S, Coyle NE, Tang H, et al. Population stratification confounds genetic association studies among Latinos. Hum Genet. 2006;118:652-664.
46. Hoggart CJ, Parra EJ, Shriver MD, et al. Control of confounding of genetic associations in stratified populations. Am J Hum Genet. 2003;72:1492-1504.